About this trial
This trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to ALND in terms of arm-related Quality of Life (QoL) and occurrence of lymphedema two years after randomization.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Written informed consent according to ICH/GCP regulations prior to any trial specific procedures.
Patients ≥ 18 years of age.
Node-positive breast cancer (histologically or cytologically proven both in primary tumor and in lymph node) American Joint Committee on Cancer/ International Union Against Cancer (AJCC/UICC) stage II-III (all molecular subtypes allowed).
Node-positivity detected by imaging and non-palpable (iN+) and confirmed by pathology.
Disqualifiers
Stage IV breast cancer.
Clinical N3c breast cancer without axillary disease (clinical N3a and clinical N3b are allowed).
Clinical N2b breast cancer (clinical N2a is allowed).
Contralateral breast cancer within 3 years.
Trial design
Parallel
Treatments tested in this trial
Axillary lymph node dissection (ALND)
Procedure/SurgerySurgical removal of lymphatic tissue within the anatomical boundaries of the axilla (standard of care in the upfront surgery setting in patients with cN+ BC)
Axillary radiotherapy (ART)
Procedure/SurgeryAxillary irradiation
Treatment groups
Trial outcomes
Primary outcomes
Change in arm-related Quality of Life (QoL)
The arm subscale (ARM) of the FACT-B+4 is used to assess arm-related QoL.The FACT-B comprises five subscales: physical well-being (seven items), social well-being (seven items), emotional well-being (six items), functional well-being (seven items), and concerns specific to patients with breast cancer (13 items). The FACT-B+4 questionnaire consists of the FACT-B subscales and the additional ARM subscale including five questions related to arm morbidity with four additional validated arm morbidity items that are added to the one item on arm morbidity already included in the FACT-B questionnaire. Patients are asked to indicate on a five- point scale from 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), to 4 (very much), to what degree each statement applied over the previous 7 days. The individual scoring of each question is inverted and added up to the total score ranging between 0 and 20 points, higher scores representing less arm problems.
Occurrence of lymphedema
Bilateral measurements will be obtained 10 cm above and 5 cm below the olecranon process on both the ipsilateral and contralateral upper extremities. The change in ipsilateral upper- extremity circumference, corrected for any change in the contralateral upper extremity, will be calculated using the following formula: L = (Ia - Ib) - (Ca- Cb). It indicates ipsilateral upper-extremity circumference, C indicates contralateral upper- extremity circumference, a indicates assessments during trial treatment and follow-up, and b indicates baseline assessment. L will be calculated for both upper arm and forearm, and lymphedema is defined as present if L \> 2 cm for either location. The proportion of patients with lymphedema will be calculated.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.